SCHEMBL10694031

SCHEMBL10694031

CC(C)NS(=O)(=O)c1ccc2c(c1)CCC2

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 1/20 0.61
ALDH3A1 P30838 1/20 0.61
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA7 P43166 1/20 0.56
CA14 Q9ULX7 1/20 0.56
DPP4 P27487 1/20 0.55
LMNA P02545 4/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
POLB P06746 1/20 0.52
PNMT P11086 2/20 0.52
ALDH1A1 P00352 6/20 0.51
KDM4E B2RXH2 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
THRB P10828 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
PTGES2 Q9H7Z7 2/20 0.50
BRD1 O95696 2/20 0.49
BRPF1 P55201 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10154039 0.82 PNMT (0.64) CA12CA1CA2CA7CA14
SCHEMBL19627414 0.80 ALDH1A1 (0.55) ALDH3A1CA12CA1CA2CA7
Hydrochloric Acid SCHEMBL28415979 0.79 PNMT (0.59) GFERALDH3A1PNMTALDH1A1HTR2C
SCHEMBL9364845 0.79 PNMT (0.64) CA12CA1CA2CA7CA14
SCHEMBL19718863 0.79 CA12 (0.59) ALDH3A1CA12CA1CA2CA7
SCHEMBL19627388 0.79 KDM4E (0.51) CA12CA1CA2CA7CA14
SCHEMBL19630913 0.77 TDP1 (0.56) CA12CA1CA2CA7CA14
SCHEMBL12828070 0.76 CA12 (0.66) ALDH3A1CA12CA1CA2CA7
SCHEMBL30304230 0.76 HTR2C (0.76) CA12CA1CA2CA7CA14
SCHEMBL21776394 0.75 ALDH1A1 (0.63) DPP4LMNASMN1; SMN2POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208968-A1 ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF DICE MOLECULES SV, INC. 2024-06-27 US disclosed
US-20240208968-A1 ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF DICE MOLECULES SV, INC. 2024-06-27 US disclosed
US-4724235-A N-(arylthioalkyl)-N'-(aminoalkyl)ureas useful in the treatment of arrhythmia A. H. ROBINS COMPANY, INCORPORATED (US) 1988-02-09 US disclosed
US-4597902-A TREATMENT OF CARDIAC ARRHYTHMIAS A. H. ROBINS COMPANY, INCORPORATED (US) 1986-07-01 US disclosed
EP-0066415-B1 N-(ARYLTHIOALKYL)-N'-(AMINOALKYL)UREAS A.H. ROBINS COMPANY, INCORPORATED (US) 1985-10-02 EP disclosed
EP-0066415-A2 N-(arylthioalkyl)-N'-(aminoalkyl)ureas A.H. ROBINS COMPANY, INCORPORATED (US) 1982-12-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208968-A1 ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF ITGB1, ITGA1, ITGAV GFER 3419/4885ALDH3A1 1620/4885CA12 2865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.